Analyses / NKE
Apparel giant near 52-week lows; downgrade headwind and margin compression drive caution.
A free account reveals NKE's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.
The Thesis
▲ Bull Case
Stock down 52% from 52-week high ($76.97) offers entry for a mega-cap with 42.9% gross margin, 1.37% dividend yield, and strong balance sheet (1.96x current ratio). If operational headwinds ease and sentiment stabilizes, mean-reversion upside to $55–65 possible within 12 months. Insider buying (25 vs 27 sells) shows mixed but present conviction.
▼ Bear Case
EPS down 13.4% YoY and 10% over 5Y; revenue flat (+0.8% 5Y, -3.2% YoY) signals structural demand weakness. Operating margin compressed to 8.2%; payout ratio 77.5% limits reinvestment. Baird downgrade (Outperform → Neutral) and CLO share selling at 52-week lows fuel near-term risk. Multiple still at 17.6x forward P/E leaves little room for further miss.
Valuation
MIXED — undervalued on absolute metrics, but growth and profitability deterioration justify modest discount — score 58/100
P/E 17.6x forward is reasonable for a mature blue-chip, but forward P/E = current P/E signals zero earnings growth assumption. P/S 1.18x and EV/EBITDA 12.1x are not cheap enough to offset negative EPS/revenue trends. P/B 4.58x high, but book value includes intangibles; tangible book 9.86 anchors downside. Price-to-FCF 25x is expensive—FCF generation under pressure.
Technical Levels
Support · $36.55 (52-week low (near current)) · $35.00 (psychological round) · $33.00 (major capitulation target)
Resistance · $37.41 (day high) · $40.00 (round number + 8% upside) · $45.00 (20-day VWAP zone (est)) · $50.00 (key retracement)
RSI: unknown (not in payload)
Financial Health
Score 72/100. Balance sheet solid: 1.96x current, 1.19x quick. Liquidity not stressed. Payout ratio 77.5% leaves little margin for error if earnings decline. Debt metrics unavailable. Overall: near-term solvency safe; dividend sustainability questionable if earnings miss persists.
Catalysts
| Q2 FY2025 Earnings (likely Oct/Nov 2024 timeframe) | unknown (not in payload) | high |
| Management guidance revision or stabilization signal | within earnings call | high |
| Dividend confirmation or cut | earnings or shareholder update | high |
| Gross margin recovery or further compression | quarterly reporting | high |
| Analyst re-rating on operational stabilization | post-earnings, 1–3 months | medium |
Risk Flags
See NKE's full trade plan — free
Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.
Unlock NKE free →Recent News
You've read your 2 free analyses
Create a free account for unlimited analyses — every name on the page, plus live tools on 5,000+ tickers. No card required.
Read the full NKE analysis — free →Free to read · 2 analyses every 30 days without an account
More Analyses
NKE FAQ
Is NKE a buy right now?
Nike Inc's current read is a value recovery / turnaround setup with 58 confidence over a 3–6 months horizon. Valuation: MIXED — undervalued on absolute metrics, but growth and profitability deterioration justify modest discount. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.
Is NKE overvalued?
MIXED — undervalued on absolute metrics, but growth and profitability deterioration justify modest discount (valuation score 58/100). P/E 17.6x forward is reasonable for a mature blue-chip, but forward P/E = current P/E signals zero earnings growth assumption. P/S 1.18x and EV/EBITDA 12.1x are not cheap enough to offset negative EPS/revenue trends. P/B 4.58x high, but book value includes intangibles; tangible book 9.86 anchors downside. Price-to-FCF 25x is expensive—FCF generation under pressure.
What are the risks of buying NKE?
EPS down 13.4% YoY and 10% over 5Y; revenue flat (+0.8% 5Y, -3.2% YoY) signals structural demand weakness. Operating margin compressed to 8.2%; payout ratio 77.5% limits reinvestment. Baird downgrade (Outperform → Neutral) and CLO share selling at 52-week lows fuel near-term risk. Multiple still at 17.6x forward P/E leaves little room for further miss.